Acetylcholine release machinery at presynaptic cholinergic nerve terminal

The acetylcholine release machinery at presynaptic cholinergic nerve terminals refers collectively to the set of specialized molecular structures and protein complexes responsible for storing, mobilizing, and releasing acetylcholine (ACh) from neurons into the synaptic cleft. This process is essential for chemical neurotransmission at both central and peripheral synapses. Key features include: *Synaptic vesicles* containing ACh are clustered near active zones within the presynaptic terminal. Upon arrival of an action potential, voltage-gated calcium channels open in response to depolarization[4][6]. The resulting influx of Ca(^(2+)) triggers a cascade involving SNARE proteins that mediate docking and fusion of ACh-containing vesicles with the plasma membrane[2][6]. Released ACh diffuses across the synapse to activate postsynaptic receptors. Presynaptically located muscarinic and nicotinic acetylcholine receptors modulate further ACh secretion via feedback mechanisms—M1 muscarinic receptors enhance while M2 inhibit additional transmitter release[1][3]. Additional modulation occurs through other receptor systems such as adrenergic or neurotrophin pathways that influence Ca(^(2+)) channel activity or intracellular signaling cascades[3][5]. This "machinery" is not a single protein or canonical drug target but rather an integrated system comprising ion channels (especially voltage-gated calcium channels), SNARE/fusion proteins (such as syntaxin, SNAP25), regulatory G-proteins/receptors on the terminal membrane, transporters like VAChT for loading vesicles with ACh, and associated cytoskeletal elements. Dysfunction in any component can contribute to neurological diseases including neurodegeneration or neuromuscular disorders[7]. Because this term describes a multi-component process/system rather than one discrete molecule or receptor classically considered a therapeutic target—and because it lacks standardization as an official druggable entity—it should be flagged as *not* being a canonical therapeutic target. “Acetylcholine when released from nerve endings upon action potential-driven depolarization... regulates its own secretion from presynaptic terminal... Various subtypes of muscarinic and nicotinic acetylcholine receptors are expressed in motor nerve endings and they modulate release...” [1] “The neuromuscular junction... is controlled by interactions between motoneurons... The presynaptic motor nerve terminal dictates synthesis, storage & release...” [6]

Other names

Presynaptic acetylcholine release machineryCholinergic presynaptic release apparatusPresynaptic cholinergic exocytosis complex

Mechanisms are specific to individual molecular components; for example, botulinum toxin inhibits SNARE-mediated vesicle fusion.